Dr. Mell on Toxicities Associated With GL-ONC1 for Head and Neck Cancer

Loren K. Mell, MD
Published: Wednesday, Sep 23, 2015



Loren K. Mell, MD, chief, Head and Neck Malignancy Service, associate professor, University of California, San Diego, discusses toxicities associated with GL-ONC1 for the treatment of patients with head and neck cancer.

GL-ONC1 is an attenuated vaccinia virus that demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy for patients with locoregionally advanced head and neck cancer, as seen in a phase I study.

GL-ONC1 was found to be a well-tolerated agent in this study. The most common adverse events observed were low-grade, short-term rash and flu-like symptoms. Based on the foundation of GL-ONC1, its safety profile was expected. However, researchers were unsure if the agent would be just as tolerable when combined with chemotherapy.



Loren K. Mell, MD, chief, Head and Neck Malignancy Service, associate professor, University of California, San Diego, discusses toxicities associated with GL-ONC1 for the treatment of patients with head and neck cancer.

GL-ONC1 is an attenuated vaccinia virus that demonstrated safety and clinical benefit when delivered intravenously with concurrent chemoradiation therapy for patients with locoregionally advanced head and neck cancer, as seen in a phase I study.

GL-ONC1 was found to be a well-tolerated agent in this study. The most common adverse events observed were low-grade, short-term rash and flu-like symptoms. Based on the foundation of GL-ONC1, its safety profile was expected. However, researchers were unsure if the agent would be just as tolerable when combined with chemotherapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x